Integrated BioPharma, Inc. is a well-established biopharma company serving the varied needs of the nutraceutical, biotech and pharmaceutical industries. Through a number of wholly owned subsidiaries INB develops, manufactures and distributes, worldwide over 130 products.
| Revenue (Most Recent Fiscal Year) | $43.87M |
| Net Income (Most Recent Fiscal Year) | $-2.84M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.13 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.32 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -5.84% |
| Net Margin (Trailing 12 Months) | -6.48% |
| Return on Equity (Trailing 12 Months) | -14.78% |
| Return on Assets (Trailing 12 Months) | -11.24% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.00 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.42 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 4.77 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.57 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.10 |
| Exchange | NASDAQ |
| Sector | Consumer Defensive |
| Industry | Packaged Foods |
| Common Shares Outstanding | 30.98M |
| Free Float | 10.10M |
| Market Capitalization | $5.58M |
| Average Volume (Last 20 Days) | 0.02M |
| Beta (Past 60 Months) | 0.50 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 67.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 25.25% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |